The Sapphire II test by Cognoptix showed a sensitivity of 85% and specificity of 95% in differentiating 20 patients diagnosed with probable Alzheimer’s disease from a group of 20 age-matched controls, according to a company press release.
The Sapphire II test by Cognoptix showed a sensitivity of 85% and specificity of 95% in differentiating 20 patients diagnosed with probable Alzheimer’s disease from a group of 20 age-matched controls, according to a company press release.